Anthem Bioscienc

Why is Anthem Biosciences Ltd falling/rising?

As of 23-Jun, Anthem Biosciences Ltd's stock price has risen to 774.45, reflecting an increase of 1.08%. This rise is driven by improved investor sentiment, strong financial performance, and increased institutional investor participation.

As of 23-Jun, Anthem Biosciences Ltd is experiencing a rise in its stock price, currently at 774.45, reflecting an increase of 8.3 (1.08%). This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 0.33% today, indicating a positive trend in comparison to its peers. Additionally, there has been a trend reversal as the stock has gained after two consecutive days of decline, suggesting a recovery in investor sentiment.<BR><BR>The stock reached an intraday high of Rs 785.5, which is a 2.53% increase, further demonstrating its positive momentum. Despite a slight decrease in delivery volume by 15.06% against the 5-day average, the stock remains liquid enough for trading, with a delivery volume of 3.53 lacs on 22 Jun.<BR><BR>Moreover, the company has shown strong long-term fundamental strength, with an average Return on Equity (ROE) of 19.93% and a significant annual growth rate of 44.32% in operating profit. The recent positive financial results declared in March 2026, including a 43.0% growth in profit before tax and record net sales, have likely bolstered investor confidence. Additionally, the increase in institutional investor participation, with a 3.87% rise in their stake, suggests a growing trust in the company's prospects.<BR><BR>Overall, these factors contribute to the stock's rising price, reflecting a combination of positive performance metrics, investor sentiment, and institutional backing.

Which are the latest news on Anthem Bioscienc?

What does Anthem Bioscienc do?

Anthem Biosciences Ltd is a Mid Cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 611 Cr and a net profit of 190 Cr for the quarter ending March 2026. It has a market cap of INR 43,400 Cr and key metrics include a P/E ratio of 71.00 and a return on equity of 21.62%.

Overview:<BR>Anthem Biosciences Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Mid Cap company.<BR><BR>History:<BR>Anthem Biosciences Ltd was originally incorporated as "Anthem Biosciences Private Limited" in 2006. The company transitioned from a Private to a Public Company and changed its name to "Anthem Biosciences Limited," with the conversion certified on December 10, 2024. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 611 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 190 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 43,400 Cr (Mid Cap) <BR><BR>Key Metrics:<BR>P/E: 71.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.28 <BR>Return on Equity: 21.62% <BR>Price to Book: 13.71 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

How big is Anthem Bioscienc?

As of 10th June, Anthem Biosciences Ltd has a market capitalization of 43,400.00 Cr and reported net sales of 2,124.33 Cr and net profit of 591.80 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Anthem Biosciences Ltd has a market capitalization of 43,400.00 Cr, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 2,124.33 Cr, while the sum of Net Profit for the same period is 591.80 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds stand at 2,409.86 Cr, and Total Assets are valued at 2,789.64 Cr.

Who are the peers of the Anthem Bioscienc?

Anthem Bioscienc's peers include Laurus Labs, Biocon, Alkem Lab, Glenmark Pharma, Abbott India, Ipca Labs, Gland Pharma, Ajanta Pharma, and Glaxosmi. Pharma. Anthem Bioscienc shows excellent growth and capital structure, while its peers vary in management risk and return performance.

Peers: The peers of Anthem Bioscienc are Laurus Labs, Biocon, Alkem Lab, Glenmark Pharma, Abbott India, Ipca Labs, Gland Pharma, Ajanta Pharma, and Glaxosmi. Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Abbott India, Ajanta Pharma, and Glaxosmi. Pharma, while Good management risk is found at Laurus Labs, Alkem Lab, Glenmark Pharma, Anthem Bioscienc, Ipca Labs, Gland Pharma, and J B Chemicals &. Average management risk is present at Biocon. In terms of Growth, Anthem Bioscienc stands out with Excellent growth, while Good growth is noted at Glenmark Pharma and the rest have Below Average growth. For Capital Structure, Excellent ratings are given to Alkem Lab, Abbott India, Anthem Bioscienc, Ajanta Pharma, Glaxosmi. Pharma, and J B Chemicals &, while Average is noted at Laurus Labs and Good at Glenmark Pharma, Ipca Labs, and Gland Pharma.<BR><BR>Return Snapshot: Laurus Labs has the highest 1-year return at 106.26%, while Glaxosmi. Pharma has the lowest at -36.12%. Anthem Bioscienc does not have a 1-year return available for comparison. Additionally, Abbott India and Glaxosmi. Pharma have negative six-month returns.

Should I buy, sell or hold Anthem Biosciences Ltd?

Are Anthem Biosciences Ltd latest results good or bad?

Anthem Biosciences Ltd's latest Q4 FY26 results are strong, with a net profit increase of 104.44% quarter-over-quarter and revenue up 44.38%. However, the stock's high valuation has led analysts to issue a cautious "SELL" rating, resulting in a mixed overall assessment.

Anthem Biosciences Ltd's latest results for Q4 FY26 are quite strong, indicating a significant turnaround from the previous quarter. The company reported a net profit of ₹189.76 crores, which is a remarkable increase of 104.44% quarter-over-quarter and 129.68% year-over-year. Revenue also saw a substantial rise, reaching ₹610.94 crores, reflecting a 44.38% increase from the previous quarter and a 26.44% increase compared to the same quarter last year.<BR><BR>Additionally, the operating margin has improved to 43.74%, marking the highest level in eight quarters, which demonstrates enhanced operational efficiency. The return on equity stands at a solid 24.12%, showcasing strong capital efficiency.<BR><BR>However, despite these impressive financial metrics, the stock is trading at a high valuation of 72 times trailing earnings and 15.30 times book value, which is significantly above industry averages. This elevated valuation has led analysts to adopt a cautious stance, with a "SELL" rating on the stock.<BR><BR>In summary, while the financial performance is strong and shows positive growth trends, the high valuation raises concerns about the sustainability of such multiples, making the overall assessment mixed.

Has Anthem Biosciences Ltd declared dividend?

Yes, Anthem Biosciences Ltd has declared a 100% dividend, with an ex-date of June 25, 2026. However, the company has shown no price or dividend returns over the longer periods, indicating a need for performance improvement.

Anthem Biosciences Ltd has declared a 100% dividend.<BR><BR>Dividend Details:<BR>Percentage announced: 100%<BR>Ex-date: 25 Jun 26<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 3 months, Anthem Biosciences Ltd achieved a price return of 13.0%, a dividend return of 0.29%, resulting in a total return of 13.29%.<BR><BR>Over the past 6 months, the company recorded a price return of 21.11%, a dividend return of 0.32%, leading to a total return of 21.43%.<BR><BR>For the 1-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the 2-year period, the company saw no price return or dividend return, culminating in a total return of 0.0%.<BR><BR>Over the last 3 years, there were no price or dividend returns, resulting in a total return of 0.0%.<BR><BR>In the 4-year period, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>Finally, in the 5-year period, there were no price or dividend returns, resulting in a total return of 0.0%.<BR><BR>Overall, while Anthem Biosciences Ltd has declared a significant dividend, the total returns over the longer periods indicate a lack of growth in price and dividends, suggesting a need for improvement in performance.

When is the next results date for Anthem Biosciences Ltd?

The next results date for Anthem Biosciences Ltd is 19 May 2026.

The next results date for Anthem Biosciences Ltd is scheduled for 19 May 2026.

How has been the historical performance of Anthem Bioscienc?

Anthem Bioscienc experienced significant growth from March 2024 to March 2025, with net sales rising to 1,844.55 Cr and profit after tax increasing to 451.26 Cr. Key metrics such as operating profit and cash flow also improved, reflecting strong financial performance.

Answer:<BR>The historical performance of Anthem Bioscienc shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Anthem Bioscienc reported net sales of 1,844.55 Cr in March 2025, an increase from 1,419.37 Cr in March 2024. The total operating income also rose to 1,844.55 Cr from 1,419.37 Cr, while total expenditure increased to 1,173.72 Cr from 914.40 Cr. This led to an operating profit (PBDIT) of 756.56 Cr, up from 568.67 Cr the previous year. Profit before tax reached 656.87 Cr, compared to 477.32 Cr in the prior year, resulting in a profit after tax of 451.26 Cr, which was higher than 367.31 Cr in March 2024. The earnings per share increased to 8.07 from 6.57, and the operating profit margin improved slightly to 36.37% from 35.58%. On the balance sheet, total assets grew to 2,789.64 Cr from 2,356.72 Cr, while total liabilities also increased to 2,789.64 Cr from 2,356.72 Cr. The cash flow from operating activities saw a notable rise to 418.00 Cr from 140.00 Cr, contributing to a net cash inflow of 132.00 Cr, reversing the outflow of 158.00 Cr in the previous year. Overall, Anthem Bioscienc demonstrated robust growth in sales, profits, and cash flow, indicating a strong financial performance.

Is Anthem Bioscienc overvalued or undervalued?

As of August 29, 2025, Anthem Bioscienc is considered very expensive with a PE ratio of 90.82 and other high valuation metrics, indicating it is overvalued compared to peers, despite a recent positive return of 4.51%.

As of 29 August 2025, the valuation grade for Anthem Bioscienc has moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a PE ratio of 90.82, a Price to Book Value of 18.59, and an EV to EBITDA ratio of 65.82. These ratios are considerably higher than its peers, such as Sun Pharma with a PE of 33.34 and Divi's Lab at 70.28, both of which are categorized as expensive or very expensive.<BR><BR>In comparison to other companies in the pharmaceuticals and biotechnology sector, Anthem Bioscienc's high valuation metrics suggest that investors are paying a premium for its stock. The PEG ratio is notably at 0.00, which raises concerns about growth expectations not being met. While the stock has shown a positive return of 4.51% over the past month compared to a decline in the Sensex, the overall valuation still points to an overvaluation scenario.